Biocartis wraps up $100m in Series C financing
This article was originally published in Scrip
Swiss molecular diagnostics specialist Biocartis has just closed a €71m ($100m) series C funding round, which included existing investor and collaborator Johnson & Johnson. It is one of the largest fundraisings in the life sciences sector this year, which is toppedby the $150 million series C round into medtech drug delivery company Valeritas in September and just behind the $107m raised by heart device firm Cameron Health in May. The round is also the second largest venture financing by a European company this year. The largest European venture financing to date has been the $132 million Series E round into Symphogen in January and just ahead of the £60 million raised by the UK inflammation company Circassia in April.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.